She was diagnosed with ocular melanoma that began when the freckle in the back of her eye became malignant. “I never even ...

Megan McClay, from Wymondham in Norfolk, has ocular melanoma, a type of eye cancer that forms in the cells that produce pigment. It is extremely rare - affecting around five in one million adults.

In a presentation at the Retina Society meeting in Lisbon, Portugal, Ivana Kim, MD, explained that AU-011 (Bel-Sar) ...

Uveal melanoma is the most common primary malignancy ... and Medicine/Molecular Oncology, Director, Ocular Oncology Service, Washington University School of Medicine, 660 South Euclid Avenue ...

Melanoma is a type of skin cancer. When it spreads to other places in your body, it's called metastatic, or advanced. If you have fair skin or you’ve spent lots of time in the sun, it’s a ...

The therapy for early-stage choroidal melanomas preserved vision in 90% of patients with no serious treatment-related adverse effects.

Eighteen months ago she was told her ocular melanoma had advanced to stage four, spread to her liver and she had an estimated two years to live. "I'm able to have a perspective on what is ...

Aura Biosciences shares rose Thursday morning in premarket trading after reporting positive study results for bel-sar, its ocular cancer treatment. The stock traded 7.5% higher ahead of the morning ...

Bo Crane (Robert L. Crane, Jr) passed away on August 21, 2024 at home after a brave 6-year struggle with ocular melanoma. Bo ...

Aura Biosciences announces positive results from phase 2 end of study of bel-sar as a first-line treatment for early-stage choroidal melanoma: Boston Saturday, September 14, 2024, ...

which are to advance its use for the treatment of patients with 2nd-line previously treated cutaneous melanoma [CM] and as an adjuvant for uveal [ocular] melanoma. The former study expected to ...

1 The Phase 2 results are a significant achievement considering the typically poor prognosis associated with choroidal melanoma, a rare and life-threatening ocular cancer, where there are no approved ...